Details for Patent: 8,921,326
✉ Email this page to a colleague
Which drugs does patent 8,921,326 protect, and when does it expire?
Patent 8,921,326 protects LUPRON DEPOT and LUPRON DEPOT-PED KIT and is included in two NDAs.
This patent has thirty-five patent family members in twenty-eight countries.
Summary for Patent: 8,921,326
| Title: | Sustained-release composition and method for producing the same |
| Abstract: | Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same. |
| Inventor(s): | Futo; Tomomichi (Osaka, JP), Saito; Kazuhiro (Osaka, JP), Hoshino; Tetsuo (Osaka, JP), Hori; Masuhisa (Osaka, JP) |
| Assignee: | Takeda Pharmaceutical Company Limited (Osaka, JP) |
| Application Number: | 12/312,751 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; Dosage form; Formulation; |
Drugs Protected by US Patent 8,921,326
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020517-003 | Jun 17, 2011 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | PALLIATIVE TREATMENT OF PROSTATE CANCER | ⤷ Sign Up | |||
| Abbvie Endocrine Inc | LUPRON DEPOT-PED KIT | leuprolide acetate | POWDER;INTRAMUSCULAR | 020263-009 | Apr 14, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,921,326
| PCT Information | |||
| PCT Filed | December 17, 2007 | PCT Application Number: | PCT/JP2007/074617 |
| PCT Publication Date: | June 26, 2008 | PCT Publication Number: | WO2008/075762 |
International Family Members for US Patent 8,921,326
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 064381 | ⤷ Sign Up | |||
| Australia | 2007335406 | ⤷ Sign Up | |||
| Brazil | PI0720582 | ⤷ Sign Up | |||
| Canada | 2671670 | ⤷ Sign Up | |||
| Chile | 2007003658 | ⤷ Sign Up | |||
| China | 101563068 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
